September 10, 2007Open Access

The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The clinical effect of octreotide correlates with the proportion of cells positive for SSTR2a in immunohistochemical staining, rather than the adenoma SSTR2a protein level. There may be a down-regulation of SSTR2a during octreotide treatment.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fougner et al. (Mon,) studied this question.

synapsesocial.com/papers/69daa8f03bc1ef7225684760 https://doi.org/https://doi.org/10.1111/j.1365-2265.2007.03065.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Molecular Biology of Somatostatin Receptors*1995 · 621 citations
2Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly2001 · 181 citations
3Impact of gsp Oncogene on the Expression of Genes Coding for Gs , Pit-1, Gi2 , and Somatostatin Receptor 2 in Human Somatotroph Adenomas: Involvement in Octreotide Sensitivity1999 · 23 citations
4BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas2001 · 75 citations
5Desensitization to Somatostatin Analogue (Octreotide) Observed in a Patient with Acromegaly.1995 · 11 citations

Me gusta

Guardar

Ver artículo completo